الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 197 |  |  |
| | | from | 197 | | |
Abstract
Multiple studies showed a significant role of neuroinflammation in patients with Parkinson’s disease when compared to healthy controls. Additionally, inflammatory markers were found to have a significant impact on both motor and cognitive symptoms in PD. Also, QEEG was correlated with cognitive level in a lot of neurological and psychiatric disorders.
The aim of this work was to evaluate the role of serum TIPE2 level as a serological biomarker of severity of PD and to clarify the relation between Quantitative EEG and the cognitive impairment in PD patients.
The present study was conducted on 47 patients with idiopathic PD and 47 normal healthy controls of both sexes, with a mean age 60.48 ± 6.88 years for patients and 59.61± 7.03 years for controls. There was no statistically significant difference between patients and controls regarding age or sex.
The motor symptoms in PD patients included in our study were assessed using modified H&Y staging scale and UPDRS. The cognitive function of PD patients was assessed using MoCA that covers the full spectrum of cognitive deficits associated with PD including: executive and visuospatial functions, naming, attention, language, abstraction, delayed recall, orientation and total score
All PD patients and controls included in our study were assessed by measuring the serum level of TIPE2 using ELISA assay and BRF was calculated by QEEG analysis.
The results of our study were sumarized in the following:
1. PD patients were found to have significantly higher serum level of TIPE2 than controls.
2. Patients with cognitive impairment have a statistically significant higher serum level TIPE2 measurement than patients with no cognitive impairment.
3. Patients with severe H&Y score had a statistically significant higher TIPE2 serum level measurement than patients with moderate H&Y score Or mild HY score
4. Patients with less than 5 years disease duration had a statistically significant higher TIPE2 serum level measurement than patients with more than 5 years disease duration.
5. Patients younger than 65 years old had a statistically significant higher TIPE2 serum level measurement than patients older than 65 years.
6. PD patients were found to have higher value of BRF than controls.
7. Patients with cognitive impairment had a statistically significant lower BRF measurement than patients without cognitive impairment.
8. There was a positive correlation between TIPES serum level and bradykinesia and total motor subscores of UPDRS and total score of UPDRS.
9. There was a statistically significant negative correlation between TIPE2 serum levels and the scores of executives and visuspatial functions, Attention, Abstraction and Total score of MoCA.
10. There was a significant positive correlation between age of the patients and serum levels of TIPE2.
11. There was no significant correlation between serum levels of TIPE2 and BRF.
12. There was a statistically significant negative correlation between BRF and the scores of UPDRS (bradykinesia, total motor, mentation, and total score).
13. There was a statistically significant positive correlation between BRF and the scores of attention and total MoCA score.
Conclusion:
PD patients were found to have significantly higher TIPE2 serum levels than healthy controls.Cognitivly impairmed PD patients were also found to have significally higher serum level of TIPE2 than patients without cognitive impairment.Such relation may suggest that TIPE2 maybe considered as a serological biomarker for PD severity and PDD.
PD patients have higher BRF levels than healthy controls. This difference was significant between PD patients with and without cognitive impairment.